Novo Nordisk reaches whistleblower settlement in 'white-coat' sales scheme lawsuit

Novo Nordisk
Novo Nordisk reached a settlement deal in a lawsuit alleging the company ran a "white-coat marketing scheme," according to a spokesperson.

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and Levemir.

According to the suit (PDF)—recently unsealed as part of the settlement process—Novo Nordisk partnered with a clinical education company, Healthstar’s PT, to set up a program dubbed Changing Life with Diabetes. The group hired and trained certified diabetes educators (CDEs), according to the suit, which was brought by two former managers and more than two dozen states.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The whistleblowers claim that since 2006, Novo ran the program to gain crucial access at physician practices, where CDEs would provide thousands of dollars worth of educational programs and materials. According to the lawsuit, CDEs would provide:

  • Free patient education and seminars;
  • Free, in-office training;
  • Free Novo-branded log books to give to patients; and
  • Unlimited access to “Go To” diabetes experts for patients.

A Novo spokesperson said the drugmaker “reached an agreement in principle to settle certain claims related to this investigation.”

RELATED: Lawmakers suggest Lilly, Novo, Sanofi colluded on insulin prices, call for probe

“We deny the allegations, and highly value the role our diabetes educators serve in helping HCPs better understand diabetes and patient care,” Novo’s spokesperson said via email. “The process is not finalized, and as such we can’t provide further comment to this matter at this time.”

The idea behind the program, according to the suit, was to induce prescribers to write scripts for Novo’s diabetes meds by offering such services. CDEs could develop a closer bond with docs than sales reps could, and the companies were “extraordinarily successful” in boosting sales with the program, the suit says.

RELATED: U.S. payer pressures force Novo Nordisk to cut loose 1,000 staffers

PhRMA code prohibits gifts or educational services worth more than $100, the lawsuit says.

It’s not the only legal action the Danish drugmaker is facing. Along with peers Sanofi and Eli Lilly, the company has been the focus of congressional scrutiny on insulin prices, with Sen. Bernie Sanders and Rep. Elijah Cummings calling for an official investigation. The drugmaker also faces a pair of class action lawsuits over insulin pricing.

Aside from those challenges, U.S. pricing pressures have taken a toll at Novo lately, forcing the company to cast off 1,000 staffers last fall.

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.